Abstract
Primary malignant central nervous system (CNS) tumors only represent about 2% of all cancers. However, they are very often associated with high morbidity and mortality. Despite current standard-of-care therapy, such as surgery, irradiation, and chemotherapy, neither cure nor any toxic therapy against malignant CNS tumors has been developed so far. Nanotechnology may alter this situation. It offers a new promise for cancer diagnosis and treatment. This emerging technology, by developing and manufacturing materials using atomic and molecular elements, can provide a platform for the combination of diagnostics, therapeutics and delivery to the tumor, with subsequent monitoring of the response. This review focuses on recent developments in cancer nanotechnology with particular attention to nanoparticle systems, important tools for the improvement of drug delivery in brain tumor. The latest advances in both the research sector and in recent patents for cancer imaging and therapy are discussed.
Keywords: Cancer treatment, drug delivery, gene therapy, nanotechnology, nanoparticle, patent, Glioma vasculature, Fluorescein, Magnetofluorescent nanoprobes, Liposomes, Gold NPs, Quantum dots, Magnetic nanocrystals, Dye-loaded NPs, Immunotargeted nanoshells, SPIONs, FITC, photoacoustic computed, omography (PAT), ZnCdS, EGFR, AS1411 aptamer, Chitosan, Hydrogels, PEGylated PHDCA, spinal neoplasm, LSFV-IL12, HSV-1-tk, EpCAM, MWCNTs, Nanostructure Enhanced X-ray Therapy, CAT scan, cGMP
Recent Patents on Anti-Cancer Drug Discovery
Title: Nanotechnology Advances in Brain Tumors: The State of the Art
Volume: 6 Issue: 1
Author(s): Gloria Invernici, Silvia Cristini, Giulio Alessandri, Stefania E. Navone, Laura Canzi, Daniela Tavian, Chiara Redaelli, Francesco Acerbi and Eugenio A. Parati
Affiliation:
Keywords: Cancer treatment, drug delivery, gene therapy, nanotechnology, nanoparticle, patent, Glioma vasculature, Fluorescein, Magnetofluorescent nanoprobes, Liposomes, Gold NPs, Quantum dots, Magnetic nanocrystals, Dye-loaded NPs, Immunotargeted nanoshells, SPIONs, FITC, photoacoustic computed, omography (PAT), ZnCdS, EGFR, AS1411 aptamer, Chitosan, Hydrogels, PEGylated PHDCA, spinal neoplasm, LSFV-IL12, HSV-1-tk, EpCAM, MWCNTs, Nanostructure Enhanced X-ray Therapy, CAT scan, cGMP
Abstract: Primary malignant central nervous system (CNS) tumors only represent about 2% of all cancers. However, they are very often associated with high morbidity and mortality. Despite current standard-of-care therapy, such as surgery, irradiation, and chemotherapy, neither cure nor any toxic therapy against malignant CNS tumors has been developed so far. Nanotechnology may alter this situation. It offers a new promise for cancer diagnosis and treatment. This emerging technology, by developing and manufacturing materials using atomic and molecular elements, can provide a platform for the combination of diagnostics, therapeutics and delivery to the tumor, with subsequent monitoring of the response. This review focuses on recent developments in cancer nanotechnology with particular attention to nanoparticle systems, important tools for the improvement of drug delivery in brain tumor. The latest advances in both the research sector and in recent patents for cancer imaging and therapy are discussed.
Export Options
About this article
Cite this article as:
Invernici Gloria, Cristini Silvia, Alessandri Giulio, E. Navone Stefania, Canzi Laura, Tavian Daniela, Redaelli Chiara, Acerbi Francesco and A. Parati Eugenio, Nanotechnology Advances in Brain Tumors: The State of the Art, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (1) . https://dx.doi.org/10.2174/157489211793979990
DOI https://dx.doi.org/10.2174/157489211793979990 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Brief Review of the Essential Role of Nanovehicles for Improving the Therapeutic Efficacy of Pharmacological Agents Against Tumours
Current Drug Delivery Signal Transduction Therapy for Cancer - Whither Now?
Current Signal Transduction Therapy Ribozymes in the Age of Molecular Therapeutics
Current Molecular Medicine Imaging Adoptive Cell Transfer Based Cancer Immunotherapy
Current Pharmaceutical Biotechnology GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma
Current Drug Targets Systems Biology of Apoptosis and Survival: Implications for Drug Development
Current Pharmaceutical Design Neuroimaging of Cancer Patients for Psychosocial Support and Patient Care
Current Medical Imaging Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Recent Developments in Nanomedicines for Management of Various Health Issues Via Metabolism and Physico-Chemical Properties
Current Drug Metabolism Editorial (Thematic Issue: Targeting Anti-Cancer Agents and Cancer Treatments)
Anti-Cancer Agents in Medicinal Chemistry Epidermal Growth Factor Receptor as a Target for Anti-Cancer Agent Design
Anti-Cancer Agents in Medicinal Chemistry LAT1 Targeted Delivery of Methionine Based Imaging Probe Derived from M(III) Metal Ions for Early Diagnosis of Proliferating Tumours using Molecular Imaging Modalities
Current Cancer Drug Targets 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Molecular Imaging of Brain Tumors Personal Experience and Review of the Literature
Current Molecular Medicine MMP14 Regulates VEGFR3 Expression on Corneal Epithelial Cells
Protein & Peptide Letters Prodrugs in Genetic Chemoradiotherapy
Current Pharmaceutical Design Arsenic Trioxide Targets miR-125b in Glioma Cells
Current Pharmaceutical Design Genistein Potentiates the Anti-cancer Effects of Gemcitabine in Human Osteosarcoma via the Downregulation of Akt and Nuclear Factor-κB Pathway
Anti-Cancer Agents in Medicinal Chemistry Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Medicinal Chemistry of Drugs with Active Metabolites Following Conjugation
Mini-Reviews in Medicinal Chemistry